Identification

Name
Alfuzosin
Accession Number
DB00346  (APRD00490)
Type
Small Molecule
Groups
Approved, Investigational
Description

Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia]

Structure
Thumb
Synonyms
  • (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide
  • Alfuzosin
  • Alfuzosina
  • Alfuzosine
  • Alfuzosinum
  • N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
External IDs
SL 77499-10
Product Ingredients
IngredientUNIICASInChI Key
Alfuzosin Hydrochloride75046A1XTN81403-68-1YTNKWDJILNVLGX-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlfuzosinTablet, extended release10 mgOralSivem Pharmaceuticals Ulc2015-11-25Not applicableCanada
AlfuzosinTablet, extended release10 mgOralPro Doc Limitee2013-11-21Not applicableCanada
Auro-alfuzosinTablet, extended release10 mgOralAuro Pharma Inc2015-09-02Not applicableCanada
Sandoz AlfuzosinTablet, extended release10 mgOralSandoz Canada Incorporated2008-08-28Not applicableCanada
Teva-alfuzosin PrTablet, extended release10 mgOralTeva2010-08-31Not applicableCanada
UroxatralTablet, extended release10 mg/1OralSanofi Aventis2009-06-052017-08-02Us00024 4200 10 nlmimage10 27201390
UroxatralTablet, extended release10 mg/1OralPhysicians Total Care, Inc.2004-06-22Not applicableUs
UroxatralTablet, extended release10 mg/1OralStat Rx USA2009-06-05Not applicableUs
UroxatralTablet, extended release10 mg/1OralCovis Pharmaceuticals, Inc.2013-06-032016-12-16Us
UroxatralTablet, extended release10 mg/1OralConcordia Pharmaceuticals, Inc2013-06-03Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alfuzosin hydrochlorideTablet, extended release10 mg/1OralLiberty Pharmaceuticals, Inc.2012-10-02Not applicableUs
Alfuzosin HydrochlorideTablet, extended release10 mg/1OralDirectrx2015-12-21Not applicableUs
Alfuzosin HydrochlorideTablet, extended release10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2011-08-09Not applicableUs
Alfuzosin HydrochlorideTablet10 mg/1OralWockhardt2012-08-15Not applicableUs
Alfuzosin hydrochlorideTablet, extended release10 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-03-15Not applicableUs
Alfuzosin HydrochlorideTablet, film coated, extended release10 mg/1OralAurobindo Pharma2012-08-30Not applicableUs
Alfuzosin HydrochlorideTablet, extended release10 mg/1OralTorrent Pharmaceuticals Limited2011-07-18Not applicableUs
Alfuzosin HydrochlorideTablet, extended release10 mg/1OralGolden State Medical Supply2011-07-182017-10-26Us
Alfuzosin HydrochlorideTablet, extended release10 mg/1OralApotex Corporation2011-07-18Not applicableUs60505 2850 01 nlmimage10 30441840
Alfuzosin HydrochlorideTablet, extended release10 mg/1OralPhysicians Total Care, Inc.2012-02-22Not applicableUs
International/Other Brands
Alcinin (Pharmathen) / Alfasin XR (Incepta) / Alfetim (Sanofi-Aventis) / Alfoo (Dr. Reddy's) / Alfu (Rowex) / Alfuran (Terapia) / Alfusozina (Grey Inversiones) / Flotral (Ranbaxy) / Fual (Alkem) / Profuzo (Neiss) / Rantral (Ranbaxy) / Uriten (Square) / Xantral (Sanofi-Aventis) / Xelflo (Sun) / Zatral (Eskayef)
Categories
UNII
90347YTW5F
CAS number
81403-80-7
Weight
Average: 389.4488
Monoisotopic: 389.206304377
Chemical Formula
C19H27N5O4
InChI Key
WNMJYKCGWZFFKR-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
IUPAC Name
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1

Pharmacology

Indication

For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.

Structured Indications
Pharmacodynamics

Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha(1) subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha(1) agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1a adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha(1) agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity.

Mechanism of action

Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
AAlpha-1D adrenergic receptor
antagonist
Human
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
Absorption

Absorption is 50% lower under fasting conditions

Volume of distribution
  • 3.2 L/kg [healthy male middle-aged volunteers]
Protein binding

82%-90%

Metabolism

Hepatic. Alfuzosin undergoes extensive metabolism by the liver, with only 11% of the administered dose excreted unchanged in the urine. Alfuzosin is metabolized by three metabolic pathways: oxidation, O-demethylations, and N-dealkylation. The metabolites are not pharmacologically active. CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.

Route of elimination

Following oral administration of 14C-labeled alfuzosin solution, the recovery of radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% in feces and 24% in urine.

Half life

10 hours

Clearance
Not Available
Toxicity

Side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Alfuzosin can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Alfuzosin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Alfuzosin can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AcebutololAlfuzosin may increase the hypotensive activities of Acebutolol.Approved
AdrafinilAlfuzosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AliskirenAlfuzosin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlogliptinThe serum concentration of Alfuzosin can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Alfuzosin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprenololAlfuzosin may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanAlfuzosin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronAlfuzosin may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe serum concentration of Alfuzosin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazAlfuzosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineAlfuzosin may increase the hypotensive activities of Amlodipine.Approved
AmprenavirThe serum concentration of Alfuzosin can be increased when it is combined with Amprenavir.Approved
AmrinoneAlfuzosin may increase the hypotensive activities of Amrinone.Approved
AnagrelideAlfuzosin may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineAlfuzosin may decrease the vasoconstricting activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Alfuzosin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Alfuzosin can be increased when it is combined with Apixaban.Approved
ApraclonidineAlfuzosin may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Alfuzosin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Alfuzosin can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineAlfuzosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolAlfuzosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Alfuzosin can be increased when it is combined with Argatroban.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
Arsenic trioxideAlfuzosin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherAlfuzosin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineAlfuzosin may increase the QTc-prolonging activities of Asenapine.Approved
AsunaprevirThe serum concentration of Alfuzosin can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Alfuzosin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAlfuzosin may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Alfuzosin can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Alfuzosin.Approved
AzelnidipineAlfuzosin may increase the hypotensive activities of Azelnidipine.Approved, Investigational
AzimilideAlfuzosin may increase the hypotensive activities of Azimilide.Investigational
AzithromycinAlfuzosin may increase the QTc-prolonging activities of Azithromycin.Approved
BarnidipineAlfuzosin may increase the hypotensive activities of Barnidipine.Approved
BatimastatThe serum concentration of Alfuzosin can be increased when it is combined with Batimastat.Experimental
BedaquilineAlfuzosin may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Alfuzosin.Experimental
BenazeprilAlfuzosin may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneAlfuzosin may increase the hypotensive activities of Bencyclane.Experimental
BendroflumethiazideAlfuzosin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenidipineAlfuzosin may increase the hypotensive activities of Benidipine.Approved, Investigational
BenzamidineThe serum concentration of Alfuzosin can be increased when it is combined with Benzamidine.Experimental
BepridilAlfuzosin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololAlfuzosin may increase the hypotensive activities of Betaxolol.Approved
BethanidineAlfuzosin may increase the hypotensive activities of Bethanidine.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved
BietaserpineAlfuzosin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostAlfuzosin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololAlfuzosin may increase the hypotensive activities of Bisoprolol.Approved
BitolterolAlfuzosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Alfuzosin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Alfuzosin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved
BortezomibThe metabolism of Alfuzosin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Alfuzosin can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Alfuzosin may increase the hypotensive activities of BQ-123.Investigational
BretyliumAlfuzosin may increase the hypotensive activities of Bretylium.Approved
BrimonidineAlfuzosin may increase the hypotensive activities of Brimonidine.Approved
BucindololBucindolol may increase the orthostatic hypotensive activities of Alfuzosin.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Alfuzosin.Experimental, Investigational
BunazosinAlfuzosin may increase the antihypertensive activities of Bunazosin.Investigational
BupranololAlfuzosin may increase the hypotensive activities of Bupranolol.Approved
CadralazineAlfuzosin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineAlfuzosin may increase the hypotensive activities of Cafedrine.Investigational
CamostatThe serum concentration of Alfuzosin can be increased when it is combined with Camostat.Experimental
CandesartanAlfuzosin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilAlfuzosin may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilAlfuzosin may increase the hypotensive activities of Candoxatril.Experimental
CandoxatrilatThe serum concentration of Alfuzosin can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilAlfuzosin may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Alfuzosin can be increased when combined with Carbamazepine.Approved, Investigational
CarboxyamidotriazoleAlfuzosin may increase the hypotensive activities of Carboxyamidotriazole.Investigational
CaroverineAlfuzosin may increase the hypotensive activities of Caroverine.Experimental
CarteololAlfuzosin may increase the hypotensive activities of Carteolol.Approved
CarvedilolAlfuzosin may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololAlfuzosin may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Alfuzosin can be increased when it is combined with Ceritinib.Approved
ChloroquineAlfuzosin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideAlfuzosin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineAlfuzosin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneAlfuzosin may increase the hypotensive activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Alfuzosin can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Alfuzosin can be increased when it is combined with Chymostatin.Experimental
CicletanineAlfuzosin may increase the hypotensive activities of Cicletanine.Investigational
CilastatinThe serum concentration of Alfuzosin can be increased when it is combined with Cilastatin.Approved
CilazaprilAlfuzosin may increase the hypotensive activities of Cilazapril.Approved
CilnidipineAlfuzosin may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CinnarizineAlfuzosin may increase the hypotensive activities of Cinnarizine.Approved, Investigational
CiprofloxacinAlfuzosin may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineAlfuzosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideAlfuzosin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramAlfuzosin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe serum concentration of Alfuzosin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Alfuzosin can be decreased when combined with Clemastine.Approved
ClenbuterolAlfuzosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineAlfuzosin may increase the hypotensive activities of Clevidipine.Approved
ClonidineAlfuzosin may increase the hypotensive activities of Clonidine.Approved
CloranololAlfuzosin may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Alfuzosin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineAlfuzosin may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Alfuzosin can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Alfuzosin can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibAlfuzosin may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineAlfuzosin may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideAlfuzosin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Alfuzosin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideAlfuzosin may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of Alfuzosin can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Alfuzosin can be decreased when it is combined with Dabrafenib.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Alfuzosin.Investigational
DarexabanThe serum concentration of Alfuzosin can be increased when it is combined with Darexaban.Investigational
DarodipineAlfuzosin may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Alfuzosin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Alfuzosin can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinAlfuzosin may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DeferasiroxThe serum concentration of Alfuzosin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Alfuzosin can be increased when it is combined with Delanzomib.Investigational
DelaprilAlfuzosin may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Alfuzosin can be decreased when combined with Delavirdine.Approved
DeserpidineAlfuzosin may increase the hypotensive activities of Deserpidine.Approved
DetomidineAlfuzosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineAlfuzosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DiazoxideAlfuzosin may increase the hypotensive activities of Diazoxide.Approved
diethylnorspermineAlfuzosin may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineAlfuzosin may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Alfuzosin can be decreased when combined with Dihydroergotamine.Approved
DiltiazemAlfuzosin may increase the hypotensive activities of Diltiazem.Approved
DipivefrinAlfuzosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DisopyramideAlfuzosin may increase the QTc-prolonging activities of Disopyramide.Approved
DobutamineAlfuzosin may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideAlfuzosin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronAlfuzosin may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneAlfuzosin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopexamineAlfuzosin may decrease the vasoconstricting activities of Dopexamine.Investigational
DorzolamideAlfuzosin may increase the hypotensive activities of Dorzolamide.Approved
DotarizineAlfuzosin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinAlfuzosin may increase the hypotensive activities of Doxazosin.Approved
DoxycyclineThe metabolism of Alfuzosin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneAlfuzosin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolAlfuzosin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxidopaAlfuzosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EcabetThe serum concentration of Alfuzosin can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Alfuzosin can be increased when it is combined with Edoxaban.Approved
EfonidipineAlfuzosin may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElafinThe serum concentration of Alfuzosin can be increased when it is combined with Elafin.Investigational
EliglustatAlfuzosin may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilAlfuzosin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAlfuzosin may increase the hypotensive activities of Enalaprilat.Approved
EnalkirenThe serum concentration of Alfuzosin can be increased when it is combined with Enalkiren.Experimental
EndralazineAlfuzosin may increase the hypotensive activities of Endralazine.Experimental
EnzalutamideThe serum concentration of Alfuzosin can be decreased when it is combined with Enzalutamide.Approved
EpanololAlfuzosin may increase the hypotensive activities of Epanolol.Experimental
EperisoneAlfuzosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineAlfuzosin may decrease the vasoconstricting activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Alfuzosin can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineAlfuzosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineAlfuzosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EpoprostenolAlfuzosin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAlfuzosin may increase the hypotensive activities of Eprosartan.Approved
ErgotamineAlfuzosin may decrease the vasoconstricting activities of Ergotamine.Approved
ErythromycinAlfuzosin may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramAlfuzosin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved
EtilefrineAlfuzosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
FaldaprevirThe serum concentration of Alfuzosin can be increased when it is combined with Faldaprevir.Investigational
FelodipineAlfuzosin may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineAlfuzosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamAlfuzosin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolAlfuzosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidAlfuzosin may increase the hypotensive activities of Ferulic acid.Experimental
FlecainideAlfuzosin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluconazoleThe metabolism of Alfuzosin can be decreased when combined with Fluconazole.Approved
FlunarizineAlfuzosin may increase the hypotensive activities of Flunarizine.Approved
FluoxetineAlfuzosin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolAlfuzosin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvoxamineThe metabolism of Alfuzosin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolAlfuzosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Alfuzosin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Alfuzosin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilAlfuzosin may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Alfuzosin can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Alfuzosin can be increased when it is combined with Fusidic Acid.Approved
GabapentinAlfuzosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GabexateThe serum concentration of Alfuzosin can be increased when it is combined with Gabexate.Investigational
Gadobenic acidAlfuzosin may increase the QTc-prolonging activities of Gadobenic acid.Approved
GallopamilAlfuzosin may increase the hypotensive activities of Gallopamil.Investigational
GeldanamycinThe serum concentration of Alfuzosin can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemifloxacinAlfuzosin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GM6001The serum concentration of Alfuzosin can be increased when it is combined with GM6001.Experimental
GoserelinAlfuzosin may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronAlfuzosin may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzAlfuzosin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelAlfuzosin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineAlfuzosin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineAlfuzosin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineAlfuzosin may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorAlfuzosin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzAlfuzosin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanAlfuzosin may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolAlfuzosin may increase the QTc-prolonging activities of Haloperidol.Approved
HexamethoniumAlfuzosin may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineAlfuzosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineAlfuzosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydralazineAlfuzosin may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideAlfuzosin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAlfuzosin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbutilideAlfuzosin may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Alfuzosin can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Alfuzosin can be increased when it is combined with Idraparinux.Investigational
IloperidoneAlfuzosin may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Alfuzosin can be decreased when combined with Imatinib.Approved
ImidaprilAlfuzosin may increase the hypotensive activities of Imidapril.Investigational
IndapamideAlfuzosin may increase the hypotensive activities of Indapamide.Approved
IndenololAlfuzosin may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Alfuzosin can be increased when it is combined with Indinavir.Approved
IndoraminAlfuzosin may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanAlfuzosin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Alfuzosin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoetarineAlfuzosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Alfuzosin can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoprenalineAlfuzosin may decrease the vasoconstricting activities of Isoprenaline.Approved
IsoxsuprineAlfuzosin may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineAlfuzosin may increase the hypotensive activities of Isradipine.Approved
ItraconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Alfuzosin can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Alfuzosin can be increased when it is combined with Ixazomib.Approved
KetanserinAlfuzosin may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolAlfuzosin may increase the hypotensive activities of Labetalol.Approved
LacidipineAlfuzosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineAlfuzosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Alfuzosin.Investigational
LatanoprostAlfuzosin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LenvatinibAlfuzosin may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Alfuzosin can be increased when it is combined with Lepirudin.Approved
LercanidipineAlfuzosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Alfuzosin can be increased when it is combined with Letaxaban.Investigational
LeuprolideAlfuzosin may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinAlfuzosin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LidoflazineAlfuzosin may increase the hypotensive activities of Lidoflazine.Experimental
LinagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Linagliptin.Approved
LinsidomineAlfuzosin may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilAlfuzosin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineAlfuzosin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Alfuzosin can be increased when it is combined with Lopinavir.Approved
LosartanAlfuzosin may increase the hypotensive activities of Losartan.Approved
LovastatinThe metabolism of Alfuzosin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Alfuzosin can be increased when combined with Lumacaftor.Approved
LumefantrineAlfuzosin may increase the QTc-prolonging activities of Lumefantrine.Approved
MacitentanAlfuzosin may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateAlfuzosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineAlfuzosin may increase the hypotensive activities of Manidipine.Approved, Investigational
MecamylamineAlfuzosin may increase the hypotensive activities of Mecamylamine.Approved
MedetomidineAlfuzosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Alfuzosin can be increased when it is combined with Melagatran.Experimental
MephentermineAlfuzosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Alfuzosin.Experimental
MetaraminolAlfuzosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneAlfuzosin may increase the QTc-prolonging activities of Methadone.Approved
MethoserpidineAlfuzosin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineAlfuzosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineAlfuzosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethyldopaAlfuzosin may increase the hypotensive activities of Methyldopa.Approved
MetipranololAlfuzosin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneAlfuzosin may increase the hypotensive activities of Metolazone.Approved
MetoprololAlfuzosin may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineAlfuzosin may increase the hypotensive activities of Metyrosine.Approved
MibefradilAlfuzosin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineAlfuzosin may decrease the vasoconstricting activities of Midodrine.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Alfuzosin.Approved, Investigational
MinoxidilAlfuzosin may increase the hypotensive activities of Minoxidil.Approved
MirabegronAlfuzosin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Alfuzosin.Investigational
MitotaneThe serum concentration of Alfuzosin can be decreased when it is combined with Mitotane.Approved
MoexiprilAlfuzosin may increase the hypotensive activities of Moexipril.Approved
MoxifloxacinAlfuzosin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineAlfuzosin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineAlfuzosin may increase the hypotensive activities of Muzolimine.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Alfuzosin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololAlfuzosin may increase the hypotensive activities of Nadolol.Approved
NafamostatThe serum concentration of Alfuzosin can be increased when it is combined with Nafamostat.Approved, Investigational
NaftopidilAlfuzosin may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineAlfuzosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololAlfuzosin may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Alfuzosin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Alfuzosin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Alfuzosin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Alfuzosin can be increased when combined with Nevirapine.Approved
NicardipineAlfuzosin may increase the hypotensive activities of Nicardipine.Approved
NicorandilAlfuzosin may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifedipineAlfuzosin may increase the hypotensive activities of Nifedipine.Approved
NiguldipineAlfuzosin may increase the hypotensive activities of Niguldipine.Experimental
NilotinibAlfuzosin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineAlfuzosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineAlfuzosin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideAlfuzosin may increase the hypotensive activities of Nimesulide.Approved, Investigational, Withdrawn
NimodipineAlfuzosin may increase the hypotensive activities of Nimodipine.Approved
NisoldipineAlfuzosin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineAlfuzosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinThe serum concentration of Alfuzosin can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinAlfuzosin may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideAlfuzosin may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineAlfuzosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineAlfuzosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinAlfuzosin may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineAlfuzosin may decrease the vasoconstricting activities of Octopamine.Experimental
OfloxacinAlfuzosin may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Alfuzosin can be decreased when combined with Olaparib.Approved
OlmesartanAlfuzosin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolAlfuzosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatAlfuzosin may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronAlfuzosin may increase the QTc-prolonging activities of Ondansetron.Approved
OrciprenalineAlfuzosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Alfuzosin can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Alfuzosin can be increased when it is combined with Otamixaban.Investigational
OtiloniumAlfuzosin may increase the hypotensive activities of Otilonium.Experimental, Investigational
OxprenololAlfuzosin may increase the hypotensive activities of Oxprenolol.Approved
OxyfedrineAlfuzosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineAlfuzosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PalbociclibThe serum concentration of Alfuzosin can be increased when it is combined with Palbociclib.Approved
PaliperidoneAlfuzosin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatAlfuzosin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PargylineAlfuzosin may increase the hypotensive activities of Pargyline.Approved
PazopanibAlfuzosin may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololAlfuzosin may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineAlfuzosin may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Alfuzosin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumAlfuzosin may increase the hypotensive activities of Pentolinium.Approved
PerflutrenAlfuzosin may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineAlfuzosin may increase the hypotensive activities of Perhexiline.Approved, Investigational
PerindoprilAlfuzosin may increase the hypotensive activities of Perindopril.Approved
PhenobarbitalThe metabolism of Alfuzosin can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineAlfuzosin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhentolamineAlfuzosin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineAlfuzosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineAlfuzosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Alfuzosin can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Alfuzosin can be increased when it is combined with Phosphoramidon.Experimental
PimozideAlfuzosin may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilAlfuzosin may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumAlfuzosin may increase the hypotensive activities of Pinaverium.Approved
PindololAlfuzosin may increase the hypotensive activities of Pindolol.Approved
PirbuterolAlfuzosin may decrease the vasoconstricting activities of Pirbuterol.Approved
Platelet Activating FactorAlfuzosin may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideAlfuzosin may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved
PrazosinAlfuzosin may increase the hypotensive activities of Prazosin.Approved
PregabalinAlfuzosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolAlfuzosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineAlfuzosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimaquineAlfuzosin may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Alfuzosin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Alfuzosin can be increased when it is combined with Prinomastat.Investigational
ProcainamideAlfuzosin may increase the QTc-prolonging activities of Procainamide.Approved
ProcaterolAlfuzosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazineAlfuzosin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneAlfuzosin may increase the QTc-prolonging activities of Propafenone.Approved
PropranololAlfuzosin may increase the hypotensive activities of Propranolol.Approved, Investigational
PseudoephedrineAlfuzosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineAlfuzosin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilAlfuzosin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineAlfuzosin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineAlfuzosin may increase the QTc-prolonging activities of Quinine.Approved
RacecadotrilThe serum concentration of Alfuzosin can be increased when it is combined with Racecadotril.Investigational
RacepinephrineAlfuzosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineAlfuzosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilAlfuzosin may increase the hypotensive activities of Ramipril.Approved
RanolazineThe metabolism of Alfuzosin can be decreased when combined with Ranolazine.Approved, Investigational
RemikirenAlfuzosin may increase the hypotensive activities of Remikiren.Approved
ReproterolAlfuzosin may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineAlfuzosin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineAlfuzosin may increase the hypotensive activities of Reserpine.Approved, Investigational
RifabutinThe metabolism of Alfuzosin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Alfuzosin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Alfuzosin can be increased when combined with Rifapentine.Approved
RilmenidineAlfuzosin may increase the hypotensive activities of Rilmenidine.Investigational
RimiterolAlfuzosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatAlfuzosin may increase the hypotensive activities of Riociguat.Approved
RisedronateAlfuzosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RitobegronAlfuzosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineAlfuzosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Alfuzosin can be increased when it is combined with Rivaroxaban.Approved
RomifidineAlfuzosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
S-3304The serum concentration of Alfuzosin can be increased when it is combined with S-3304.Investigational
SalbutamolAlfuzosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolAlfuzosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanAlfuzosin may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Alfuzosin can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Saxagliptin.Approved
SelexipagAlfuzosin may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the hypotensive activities of Alfuzosin.Approved, Investigational
SilodosinAlfuzosin may increase the antihypertensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Alfuzosin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Alfuzosin can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanAlfuzosin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Alfuzosin can be increased when it is combined with Sivelestat.Investigational
SolabegronAlfuzosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolAlfuzosin may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilAlfuzosin may increase the hypotensive activities of Spirapril.Approved
St. John's WortThe serum concentration of Alfuzosin can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Alfuzosin can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleAlfuzosin may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SynephrineAlfuzosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Alfuzosin.Approved, Investigational
TalinololAlfuzosin may increase the hypotensive activities of Talinolol.Investigational
TamsulosinAlfuzosin may increase the antihypertensive activities of Tamsulosin.Approved, Investigational
TelaprevirThe serum concentration of Alfuzosin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinAlfuzosin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Alfuzosin can be increased when it is combined with Telithromycin.Approved
TelmisartanAlfuzosin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilAlfuzosin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinAlfuzosin may increase the antihypertensive activities of Terazosin.Approved
TerbutalineAlfuzosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerlipressinAlfuzosin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineAlfuzosin may increase the hypotensive activities of Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Alfuzosin.Experimental
TetrabenazineAlfuzosin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetrahydropalmatineAlfuzosin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineAlfuzosin may increase the hypotensive activities of Theodrenaline.Investigational
ThioridazineAlfuzosin may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Alfuzosin can be increased when it is combined with Thiorphan.Experimental
TiboloneAlfuzosin may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Alfuzosin can be decreased when combined with Ticlopidine.Approved
TicrynafenAlfuzosin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololAlfuzosin may increase the hypotensive activities of Timolol.Approved
TipranavirThe serum concentration of Alfuzosin can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineAlfuzosin may decrease the vasoconstricting activities of Tizanidine.Approved
TocilizumabThe serum concentration of Alfuzosin can be decreased when it is combined with Tocilizumab.Approved
TolazolineAlfuzosin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidAlfuzosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TolonidineAlfuzosin may increase the hypotensive activities of Tolonidine.Experimental
TorasemideAlfuzosin may increase the hypotensive activities of Torasemide.Approved
ToremifeneAlfuzosin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilAlfuzosin may increase the hypotensive activities of Trandolapril.Approved
TranilastAlfuzosin may increase the hypotensive activities of Tranilast.Approved, Investigational
TravoprostAlfuzosin may increase the hypotensive activities of Travoprost.Approved
TreprostinilAlfuzosin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretoquinolAlfuzosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrichlormethiazideAlfuzosin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinAlfuzosin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanAlfuzosin may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TulobuterolAlfuzosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UbenimexThe serum concentration of Alfuzosin can be increased when it is combined with Ubenimex.Experimental, Investigational
UdenafilUdenafil may increase the hypotensive activities of Alfuzosin.Approved, Investigational
UlinastatinThe serum concentration of Alfuzosin can be increased when it is combined with Ulinastatin.Investigational
UnoprostoneAlfuzosin may increase the hypotensive activities of Unoprostone.Approved
UrapidilAlfuzosin may increase the hypotensive activities of Urapidil.Investigational
ValsartanAlfuzosin may increase the hypotensive activities of Valsartan.Approved, Investigational
VandetanibAlfuzosin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Alfuzosin.Approved
VemurafenibAlfuzosin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Alfuzosin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Alfuzosin can be decreased when combined with Verapamil.Approved
VildagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Vildagliptin.Approved, Investigational
VincamineAlfuzosin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineAlfuzosin may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Voriconazole.Approved, Investigational
XamoterolAlfuzosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Alfuzosin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideAlfuzosin may increase the hypotensive activities of Xipamide.Experimental
XylazineAlfuzosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineAlfuzosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Alfuzosin may decrease the vasoconstricting activities of YM-178.Investigational
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Alfuzosin can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZiconotideAlfuzosin may increase the hypotensive activities of Ziconotide.Approved
ZiprasidoneAlfuzosin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilAlfuzosin may increase the hypotensive activities of Zofenopril.Experimental
ZuclopenthixolAlfuzosin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take after a meal (always the same meal), product bioavailability is reduced when taken on an empty stomach.

References

Synthesis Reference

Mathias Scheer, "Alfuzosin tablets and synthesis." U.S. Patent US20060062845, issued March 23, 2006.

US20060062845
General References
  1. McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. [PubMed:11893233]
  2. Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. [PubMed:7682910]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046]
  4. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574]
  5. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253]
External Links
Human Metabolome Database
HMDB14490
KEGG Drug
D01692
PubChem Compound
2092
PubChem Substance
46508512
ChemSpider
2008
BindingDB
50033110
ChEBI
51141
ChEMBL
CHEMBL709
Therapeutic Targets Database
DCL000664
PharmGKB
PA164774795
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Alfuzosin
ATC Codes
G04CA51 — Alfuzosin and finasterideG04CA01 — Alfuzosin
AHFS Codes
  • 12:16.04.12 — Selective Alfa-1-adrenergic Blocking Agents
FDA label
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
2Active Not RecruitingTreatmentOccasional Constipation1
2CompletedTreatmentAcute Urinary Retention1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2, 3TerminatedTreatmentBladder Dysfunction / Disseminated Sclerosis1
3CompletedNot AvailableUreteral Stent Discomfort1
3CompletedPreventionBenign Prostatic Hypertrophy (BPH) / Prostatic Hyperplasia / Urinary Retention1
3CompletedTreatmentAcute Urinary Retention / Prostatic Hyperplasia1
3CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
3CompletedTreatmentErectile Dysfunction (ED) / Lower Urinary Tract Symptoms (LUTS)1
3CompletedTreatmentHydronephrosis / Neurogenic Bladder Dysfunction1
3CompletedTreatmentNeurogenic Urinary Bladder1
3CompletedTreatmentProstatic Hyperplasia1
3CompletedTreatmentProstatitis1
3CompletedTreatmentUrinary Bladder Neurogenic1
3TerminatedTreatmentBenign Prostatic Hyperplasia (BPH)1
3TerminatedTreatmentProstatic Hyperplasia1
3TerminatedTreatmentUrinary Retention1
3Unknown StatusTreatmentRenal Stones1
3WithdrawnTreatmentUrinary Calculi1
4CompletedTreatmentBPH/LUTS/Sexual Functions1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms (LUTS)1
4CompletedTreatmentBenign Prostatic Hypertrophy (BPH)1
4CompletedTreatmentProstatic Diseases1
4CompletedTreatmentProstatic Hyperplasia4
4Unknown StatusTreatmentRenal Colic1
4WithdrawnTreatmentBenign Prostatic Hyperplasia (BPH)1
Not AvailableCompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Benign Prostatic Hypertrophy With Outflow Obstruction1
Not AvailableCompletedTreatmentProstatic Diseases1
Not AvailableUnknown StatusTreatmentBenign Prostatic Hypertrophy (BPH) / Erectile Dysfunction (ED)1
Not AvailableWithdrawnTreatmentRenal Stones1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral10 mg/1
TabletOral10 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral10 mg
Prices
Unit descriptionCostUnit
Uroxatral 10 mg 24 Hour tablet4.06USD tablet
Uroxatral 10 mg tablet3.95USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4661491No1994-01-182011-01-18Us
CA2264250No2005-07-052017-08-22Canada
US6149940Yes1998-02-222018-02-22Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.282 mg/mLALOGPS
logP2.02ALOGPS
logP1.19ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.64ChemAxon
pKa (Strongest Basic)7.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.83 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity107.11 m3·mol-1ChemAxon
Polarizability42.71 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.6215
Caco-2 permeable-0.5504
P-glycoprotein substrateSubstrate0.8105
P-glycoprotein inhibitor IInhibitor0.5971
P-glycoprotein inhibitor IINon-inhibitor0.5479
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.8722
CYP450 2D6 substrateNon-substrate0.7748
CYP450 3A4 substrateSubstrate0.7766
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8017
Ames testNon AMES toxic0.559
CarcinogenicityNon-carcinogens0.8721
BiodegradationNot ready biodegradable0.9945
Rat acute toxicity2.6826 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8527
hERG inhibition (predictor II)Inhibitor0.5929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0009000000-b390e2d32ee38fb79cf9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00dr-0039000000-1058f618ea52b7aa95e6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0aos-0195000000-97624e7dcce906c3a1ee
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0391000000-6d58b29a79c5af262723
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-1970000000-b3cb9821b3584d86539f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0i6s-1920000000-50ca3c071a5548796b3a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-5900000000-b3a86e227650a23790ec
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9400000000-9929aaf0359abea0c166
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9100000000-b3dba930d4cfe0d28a8e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0009000000-58fd75abdf178ea1b331
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0119000000-90a7799e494035d224e7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0abi-5791000000-648d5529faeac9e35dc0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9260000000-591f2bacf7d82aeba7e3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9250000000-d107a0e9675604325bb1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9340000000-f708562f3998488d7fce
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-7910000000-3fe44ce2a42f727569e2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-8900000000-dca38c682ad0b6c90b46
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0bvl-9300000000-bad5c36d48e0e93a82aa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0249000000-93552ff8c72ff220f172

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
Dialkylarylamines / Anisoles / Aminopyrimidines and derivatives / Alkyl aryl ethers / Imidolactams / Tetrahydrofurans / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Dialkyl ethers
show 4 more
Substituents
Quinazolinamine / Anisole / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine / Pyrimidine / Imidolactam / Benzenoid / Heteroaromatic compound / Tetrahydrofuran
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, tetrahydrofuranol, quinazolines (CHEBI:51141)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556]
  3. Lee M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39. [PubMed:12892027]
  4. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046]
  5. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685]
  6. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997 Jul;282(1):228-35. [PubMed:9223558]
  7. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478]
  8. Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62. [PubMed:9870119]
  9. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526]
  10. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574]
  11. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046]
  4. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685]
  5. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478]
  6. Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62. [PubMed:9870119]
  7. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526]
  8. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574]
  9. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046]
  4. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685]
  5. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478]
  6. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526]
  7. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574]
  8. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Derek Chadwick, Jamie Goode (2005). The HERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome, Novartis Foundation Symposium. Wiley. [ISBN:0470021411]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Guay DR: Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23. [PubMed:15555475]

Drug created on June 13, 2005 07:24 / Updated on December 04, 2017 13:13